

PATENT
Customer No. 22,852
Attorney Docket No. 08505.0020-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Jenkins, Peter James et al.)	Group Art Unit: 1623
)	
Application No.: 10/776,188)	Examiner: E. Peselev
)	
Filed: February 12, 2004)	
)	
For: PREPARATION AND DIABETIC)	Confirmation No.: 3089
USE OF GIBBERELLINS)	

CERTIFICATE UNDER 37 C.F.R. § 1.10 OF MAILING BY
"EXPRESS MAIL"

EV 684955774 US	February 6, 2006
USPS Express Mail Label Numbers	Date of Deposit

I hereby certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: Moya Khinealey
Moya Khinealey

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents on the attached listing. This Supplemental Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), for this

Supplemental Information Disclosure Statement, please charge the fee of \$180.00, as specified by Section 1.17(p) to our deposit account 06-0916.

Copies of the listed non-patent literature documents are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: February 6, 2006

By: Gretchen S. Peterson
Gretchen S. Peterson
Reg. No. 57,404



IDS Form PTO/SB/08: Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/776,188
Filing Date	February 12, 2004
First Named Inventor	Jenkins, Peter James
Art Unit	1623
Examiner Name	E. Peselev
Attorney Docket Number	08505.0020-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		Loudon, <i>Organic Chemistry</i> , 3 rd Ed. Redwood City, CA: Benjamin/Cummings Publishing Co., Inc., 1343-1348 (1995)	
		Sharp, <i>The Penguin Dictionary of Chemistry</i> , 5 th Ed., Harmondsworth, England: Penguin Books, 193 (1983)	
		Shurtz-Swirski et al., "Involvement of Peripheral Polymorphonuclear Leukocytes in Oxidative Stress and Inflammation in Type 2 Diabetic Patients," <i>Diabetes Care</i> , 24:104-110 (2001).	
		"Antidiabetic Drugs," <i>The Year's Drug News, Therapeutic Targets</i> Barcelona: Prous Science, 351-360 (1995).	
		Uvarov et al., <i>A Dictionary of Science</i> , 4 th Ed., Harmondsworth, England: Penguin Books, 169 (1971)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.